Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29 million.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CWsE2vP
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection
0 comments:
Post a Comment